Human protein tyrosine phosphatase inhibitors and methods of use
View Patent ↗The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.
1. The compound of the formula:
pharmaceutically acceptable salts thereof.
2. The compound according to claim 1 , wherein the compound is in the form of the ammonium salt.
3. A method for regulating an angiogenesis regulated disorder in a subject wherein the angiogenesis regulated disorder is an reduced angiogenesis disorder, the disorder chosen from skeletal muscle and myocardial ischemia, stroke, coronary artery disease, peripheral vascular disease, and coronary artery disease, comprising administering to a subject an effective amount of the compound 4-{(S)-2-[(S)-2-(methoxycarbonyl-amino)-3-phenylpropanamido]-2-[4-(thiophen-2-yl)thiazol-2-yl]ethyl}phenyl-sulfamic acid of the formula:
a pharmaceutically acceptable salt thereof.
4. The method according to claim 3 , wherein the compound is in the form of the ammonium salt.
5. A method for promoting tissue repair, regeneration, growth, and/or maintenance, comprising administering to a subject an effective amount of the compound 4-{(S)-2-[(S)-2-(methoxycarbonyl-amino)-3-phenylpropanamido]-2-[4-(thiophen-2-yl)thiazol-2-yl]ethyl}phenyl-sulfamic acid of the formula:
a pharmaceutically acceptable salt thereof.
6. The method according to claim 5 , wherein the compound is in the form of the ammonium salt.
7. The compound of the formula:
pharmaceutically acceptable salts thereof.
8. The compound according to claim 7 , wherein the compound is in the form of the ammonium salt.
9. A method for regulating an angiogenesis regulated disorder in a subject wherein the angiogenesis regulated disorder is an reduced angiogenesis disorder, the disorder chosen from skeletal muscle and myocardial ischemia, stroke, coronary artery disease, peripheral vascular disease, and coronary artery disease, comprising administering to a subject an effective amount of the compound 4-{(S)-2-(4-ethylthiazol-2-yl)-2-[(S)-2-(methoxycarbonylamino)-3-phenylpropanamido]-ethyl}phenylsulfamic acid of the formula:
a pharmaceutically acceptable salt thereof.
10. The method according to claim 9 , wherein the compound is in the form of the ammonium salt.
11. A method for promoting tissue repair, regeneration, growth, and/or maintenance, comprising administering to a subject an effective amount of the compound 4-{(S)-2-(4-ethylthiazol-2-yl)-2-[(S)-2-(methoxycarbonylamino)-3-phenylpropanamido]-ethyl}phenylsulfamic acid of the formula:
a pharmaceutically acceptable salt thereof.
12. The method according to claim 11 , wherein the compound is in the form of the ammonium salt.
13. The compound of the formula:
pharmaceutically acceptable salts thereof.
14. The compound according to claim 13 , wherein the compound is in the form of the ammonium salt.
15. A method for regulating an angiogenesis regulated disorder in a subject wherein the angiogenesis regulated disorder is an reduced angiogenesis disorder, the disorder chosen from skeletal muscle and myocardial ischemia, stroke, coronary artery disease, peripheral vascular disease, and coronary artery disease, comprising administering to a subject an effective amount of the compound 4-{(S)-2-[(S)-2-(methoxycarbonylamino)-3-phenylpropanamido]-2-(2-ethylthiazol-4-yl)ethyl}phenylsulfamic acid of the formula:
a pharmaceutically acceptable salt thereof.
16. The method according to claim 15 , wherein the compound is in the form of the ammonium salt.
17. A method for promoting tissue repair, regeneration, growth, and/or maintenance, comprising administering to a subject an effective amount of the compound 4-{(S)-2-[(S)-2-(methoxycarbonylamino)-3 -phenylpropanamido]-2-(2-ethylthiazol-4-yl)ethyl}phenylsulfamic acid of the formula:
a pharmaceutically acceptable salt thereof.
18. The method according to claim 17 , wherein the compound is in the form of the ammonium salt.
19. The compound of the formula:
pharmaceutically acceptable salts thereof.
20. The compound according to claim 19 , wherein the compound is in the form of the ammonium salt.
21. A method for regulating an angiogenesis regulated disorder in a subject wherein the angiogenesis regulated disorder is an reduced angiogenesis disorder, the disorder chosen from skeletal muscle and myocardial ischemia, stroke, coronary artery disease, peripheral vascular disease, and coronary artery disease, comprising administering to a subject an effective amount of the compound [4-((S)-2-{(S)-2-[(methoxycarbonyl)amino]-3-phenylpropanamido}-2-{2-[thiophen-2-yl]thiazol-4-yl}ethyl)phenyl]sulfamic acid of the formula:
a pharmaceutically acceptable salt thereof.
22. The method according to claim 21 , wherein the compound is in the form of the ammonium salt.
23. A method for promoting tissue repair, regeneration, growth, and/or maintenance, comprising administering to a subject an effective amount of the compound [4-((S)-2-{(S)-2-[(methoxycarbonyl)amino]-3-phenylpropanamido}-2-{2-[thiophen-2-yl]thiazol-4-yl}ethyl)phenyl]sulfamic acid of the formula:
a pharmaceutically acceptable salt thereof.
24. The method according to claim 23 , wherein the compound is in the form of the ammonium salt.
25. The compound according to claim 1 , wherein the compound is in the form of a salt of a cation chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
26. The method according to claim 3 , wherein the compound is in the form of a salt of a cation chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
27. The method according to claim 5 , wherein the compound is in the form of a salt of a cation chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
28. The compound according to claim 7 , wherein the compound is in the form of a salt of a cation chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
29. The method according to claim 9 , wherein the compound is in the form of a salt of a cation chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
30. The method according to claim 11 , wherein the compound is in the form of a salt of a cation chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
31. The compound according to claim 13 , wherein the compound is in the form of a salt of a cation chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
32. The method according to claim 15 , wherein the compound is in the form of a salt of a cation chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
33. The method according to claim 17 , wherein the compound is in the form of a salt of a cation chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
34. The compound according to claim 19 , wherein the compound is in the form of a salt of a cation chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
35. The method according to claim 21 , wherein the compound is in the form of a salt of a cation chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
36. The method according to claim 23 , wherein the compound is in the form of a salt of a cation chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.